Relevium Technologies Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Aurelio Useche
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 1000 Sherbrooke Street West Montreal QC Canada H3A 3G4
- IPO Date
- Nov 24, 2017
- Website
- releviumtechnologies.com
- Similar Companies
- Business
- Relevium Technologies Inc. Relevium Technologies Inc. (TSXV:RLV, OTCQB:RLLVF) is a Canada-based wellness portfolio company that identifies, evaluates, acquires, and operates brands and businesses in the health and wellness sector, with a primary focus on online distribution of nutraceuticals, sports nutrition, and nutri-cosmeceuticals; it operates through wholly-owned subsidiaries including BGX E-Health LLC, based in Orlando, Florida, which offers premium brands such as Bioganix, PushandPullsystem, and LeefyLyfe encompassing dietary supplements, skincare, fitness products, and consumer packaged goods distributed via major retailers like Amazon and Walmart in the US and Europe, and Biocannabix Health Corporation, which develops pediatric endo-medicinal nutraceuticals for cannabinoid therapy targeting medical cannabis markets. Founded around 2015 and headquartered at 1000 Sherbrooke Street West, Suite 2700, Montreal, Quebec, the company pursues growth through an acquisition model in consumer packaged goods, pediatric biopharma, and corporate segments, with operations spanning North America, Europe, and strategic pursuits in Latin America including Colombia. Recent developments include the completion of shares-for-debt transactions involving AIP acquiring over 65 million common shares, ongoing management cease trade order updates with bi-weekly progress disclosures as of early 2022, securing PPE contracts totaling $16 million that drove record Q2 revenues and FYE June 30, 2022 earnings, an agreement to acquire 100% of Terry Booth’s MED PPE Canada to strengthen joint venture operations, and subsidiary BGX E-Health securing a $1 million export contract for the Middle East, alongside historical expansions like positioning Biocannabix in Colombia for endo-medical cannabis and pursuing Lifeline Pharma acquisition for EU-GMP extraction and cultivation capabilities.
Relevium Technologies Completes Shares-For-Debt Transactions
Relevium Obtains Conditional TSXV Approval for the Settlement of the Outstanding Notes in Shares
Relevium Announces Settlement of the Outstanding Notes
Relevium Announces Shareholder Townhall and Conference Call
Relevium Announces Maturity of the Outstanding Convertible Debenture Notes and Begins Negotiations With Debenture Holders
Relevium Announces the Appointment of Dr. Wolfgang Renz as Chief Scientific Officer for Biocannabix Health Corporation
Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves
Biocannabix Enters Into LOI With IAM Health GmbH
Relevium Secures North American Exclusivity for Medical Examination Gloves, with First Shipment to Arrive in Los Angeles by Mid April
Relevium Announces Investor Relations Conference Call
Relevium Reports Interim First Quarter Results for the Three-Month Period Ended September 30, 2020
Relevium Reports Fiscal Year Ended June 30, 2020 Results
Relevium Issues Corporate Update on MCTO and Filing of Financial Statements
Relevium Issues Corporate Update on MCTO and Filing of Financial Statements
Relevium Issues Corporate Update on MCTO and Operations
Relevium Provides Regulatory Update on Annual Financials and Management Cease Trade Order
Relevium Provides Update to Management Cease Trade Order
Relevium Announces Delay in Filing Annual Audited Financial Statements